- Home
- CREV vs SNGX Comparison
CREV vs SNGX Comparison
Compare CREV & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- SNGX
- Stock Information
- Founded
- CREV 2007
- SNGX 1987
- Country
- CREV Ireland
- SNGX United States
- Employees
- CREV N/A
- SNGX N/A
- Industry
- CREV
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- SNGX Health Care
- Exchange
- CREV Nasdaq
- SNGX Nasdaq
- Market Cap
- CREV 7.2M
- SNGX 6.1M
- IPO Year
- CREV N/A
- SNGX 1987
- Fundamental
- Price
- CREV $2.76
- SNGX $2.30
- Analyst Decision
- CREV Strong Buy
- SNGX
- Analyst Count
- CREV 1
- SNGX 0
- Target Price
- CREV $39.00
- SNGX N/A
- AVG Volume (30 Days)
- CREV 25.5K
- SNGX 30.0K
- Earning Date
- CREV 01-01-0001
- SNGX 03-21-2025
- Dividend Yield
- CREV N/A
- SNGX N/A
- EPS Growth
- CREV N/A
- SNGX N/A
- EPS
- CREV N/A
- SNGX N/A
- Revenue
- CREV $39,261,077.00
- SNGX $364,183.00
- Revenue This Year
- CREV $40.76
- SNGX N/A
- Revenue Next Year
- CREV $86.18
- SNGX $119.78
- P/E Ratio
- CREV N/A
- SNGX N/A
- Revenue Growth
- CREV 41.52
- SNGX N/A
- 52 Week Low
- CREV $2.00
- SNGX $1.83
- 52 Week High
- CREV $22.34
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- CREV 34.70
- SNGX 45.88
- Support Level
- CREV $2.72
- SNGX $2.21
- Resistance Level
- CREV $3.79
- SNGX $2.32
- Average True Range (ATR)
- CREV 0.22
- SNGX 0.12
- MACD
- CREV -0.02
- SNGX 0.02
- Stochastic Oscillator
- CREV 4.30
- SNGX 50.00
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).